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Abstract: Among the different tools to address the antibiotic resistance crisis, bioprospecting in
complex uncharted habitats to detect novel microorganisms putatively producing original antimi-
crobial compounds can definitely increase the current therapeutic arsenal of antibiotics. Fungi from
numerous habitats have been widely screened for their ability to express specific biosynthetic gene
clusters (BGCs) involved in the synthesis of antimicrobial compounds. Here, a collection of unique
75 deep oceanic crust fungi was screened to evaluate their biotechnological potential through the
prism of their antimicrobial activity using a polyphasic approach. After a first genetic screening
to detect specific BGCs, a second step consisted of an antimicrobial screening that tested the most
promising isolates against 11 microbial targets. Here, 12 fungal isolates showed at least one an-
tibacterial and/or antifungal activity (static or lytic) against human pathogens. This analysis also
revealed that Staphylococcus aureus ATCC 25923 and Enterococcus faecalis CIP A 186 were the most
impacted, followed by Pseudomonas aeruginosa ATCC 27853. A specific focus on three fungal isolates
allowed us to detect interesting activity of crude extracts against multidrug-resistant Staphylococcus
aureus. Finally, complementary mass spectrometry (MS)-based molecular networking analyses were
performed to putatively assign the fungal metabolites and raise hypotheses to link them to the
observed antimicrobial activities.
Keywords: oceanic crust; fungi; secondary metabolites; molecular screening; antimicrobial assays
1. Introduction
Terrestrial, freshwater, and many marine habitats have been deeply investigated not
only regarding fungal diversity and the ecological features of their fungal communities,
but also for their ability to produce a large chemodiversity of secondary metabolites recog-
nized as antimicrobials, anticancer agents, immunosuppressive, etc. [1,2]. Marine fungi
have been detected in every habitat explored to date, from coastal waters to the deep
sea, including hydrothermal vents [3,4], deep subseafloor sediments [5–9] and even the
uncharted deep oceanic crust [10,11]. These deep subsurface biosphere fungal communities
appear to be mostly represented by ubiquitous taxa, for example, representatives of the
genera Penicillium, Aspergillus or Cladosporium [8,11,12], yet these are still active, performing
non-trivial functions and ecological roles as deciphered using metatranscriptomic-based
approaches. Indeed, using this mRNA-based strategy, fungi were shown to recycle com-
plex organic matter but also to interact with other communities through the expression
of biosynthetic gene clusters to produce antimicrobial compounds [9,11,13]. From an
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ecological angle, these studies highlight important contributions to the complexity and
dynamics of the deep biosphere microbiome. The ability of these fungi to produce sec-
ondary metabolites with antimicrobial activity in these habitats can be leveraged for use in
biotechnological applications.
Fungal cells can be viewed as microbial factories able to synthesize a large array
of valuable compounds [14] with one of the most recognized categories to date being
secondary metabolites with human health and industrial applications. Studies of bioactive
compounds from marine fungi have revealed thousands of novel chemical structures.
Interest in these has increased, and there have been ~50 compounds described each year in
the early 2000s, and ~300–400 compounds per year since 2013 (Rédou et al., 2016; Blunt
et al., 2018; Daletos et al., 2018). While sources of marine fungi that produce valuable
natural products are diverse, including fungi associated with algae, sponges, plant- and
wood-based habitats, fishes, corals and mollusks [15], increased investigations into marine
fungal secondary metabolites are also explained by an increasing interest in deep-sea
fungi [16].
Antibiotics have been overconsumed and misused in recent years and issues related
to antibiotic resistance have emerged, jeopardizing human health [17]. Increases in either
incidence and lethality of infectious diseases caused by pathogenic and multidrug-resistant
bacteria require a deep renewal of the antibiotic arsenal, and this effort is now supported
by numerous initiatives to address antibiotic resistance solutions [18,19]. Exploration of
marine fungal culture collections and new isolates from atypical uncharted habitats, such
as the deep biosphere, could lead to the discovery and isolation of novel antimicrobial
compounds. Indeed, transcript fungal data reported using metatranscriptomic-based
approaches include organic matter recycling [13] but also biosynthesis of antimicrobial
compounds, suggesting possible adaptive capabilities for competing with other microor-
ganisms [9,11]. The aim of this study was thus to confirm these conclusions by conducting
a first screening of the biotechnological potential of a previously established fungal culture
collection from the deep oceanic crust [11], representing one of the last great frontiers for bi-
ological exploration on Earth, with a specific focus on their ability to produce antimicrobial
compounds. The biotechnological potential of these fungal isolates was assessed using a
two-step bioprospecting approach to first identify their genetic potential, i.e., the presence
of specific biosynthetic gene clusters, and then to assess their ability to produce antimicro-
bial compounds that are effective against 11 common human pathogens using an agar plug
diffusion assay. Following this genetic mining and antimicrobial screening approach, com-
plementary mass spectrometry (MS)-based molecular networking analyses were performed
to annotate the putative metabolites and explain the observed antimicrobial activities.
2. Results and Discussion
2.1. Presence of Genes Involved in the Production of Secondary Metabolites
The first screening was processed on 75 fungal isolates which were extracted from the
whole collection of 128 deep oceanic crust fungi based on their taxonomy. Non-ribosomal
peptide synthetase (NRPS) genes were observed in 79.7% of the isolates, followed by type
III polyketide synthases (PKS), terpene synthase (TPS) and type I PKS genes detected in
47.3%, 44.6% and 40.5% of the isolates, respectively (Figure 1). Among the 58 filamentous
fungi, 57 harbored at least one of the targeted genes. Indeed, except for one isolate affiliated
to Bjerkandera adusta (UBOCC-A-118179), 13 isolates display one gene, 14 isolates have
two different genes, 15 isolates have three different genes and 15 isolates possess four
different genes, each of these conditions representing ~1/4th of the filamentous fungal
collection (Figure 1A). Among the 17 yeasts, only five harbored at least one of the targeted
genes: one isolate (6%) has one gene, two isolates (12%) have three different genes and two
isolates (12%) display four different genes (Figure 1B). As a special note, the presence of
representatives of the genus Entyloma in phylogenetic trees of both filamentous fungi and
yeasts is explained by different observed morphological features. The isolate identified as
Entyloma calendulae (UBOCC-A-118153) grew as a thallus and was thus considered as a
Mar. Drugs 2021, 19, 411 3 of 15
filamentous fungus, while the isolates identified as Entyloma ficariae (UBOCC-A-218010,
UBOCC-A-218013 and UBOCC-A-218014) exhibited colonies on Petri dishes characteristic
of yeasts.
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Dataset of fila t f l I S fingerprints (A) and yeast 26S fingerprints (B) coupled with type
I (clear blue), type III (pink) PKS, NRPS (clear green), hybrid PKS/NRPS (dark blue) and TPS
(dark green) gene occurrence using aligned multivalue bar chart. This figure was generated using
Interactive Tree of Life v2 [20].
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Among the most represented genera, i.e., Penicillium and Aspergillus, every isolate
displayed at least one targeted gene, with a median gene representation of two genes for
Penicillium and three genes for Aspergillus. Isolates affiliated to the genus Penicillium show
a high occurrence of NRPS (retrieved in ~95% of the isolates) and close distribution for
type III PKS, TPS and type I PKS with an occurrence of 45%, 45% and 38%, respectively.
Regarding isolates affiliated to the genus Aspergillus, the genetic potential was dominated
by NRPS (retrieved for all six isolates) and followed by type III PKS and TPS (representing
~85% of the Aspergillus isolates) and type I PKS (~65%). Isolates affiliated to the genera
Cladosporium, Sistotrema and Microscypha harbor an important genetic potential with a
median of 4, 3.5 and 3 represented genes, respectively. Finally, two genera represented by a
single isolate also display an important genetic potential, i.e., Neobulgaria sp. (UBOCC-A-
118154) and Ramularia coryli (UBOCC-A-118163).
Representatives of the genera Aspergillus, Penicillium and Cladosporium are frequently
retrieved in marine habitats, from coastal waters to the deep biosphere, for example, hy-
drothermal vents and deep subseafloor sediments [8,11,21]. Such taxa appear to be of
great interest in terms of biotechnological potential thanks to their abilities to produce a
diversity of secondary metabolites, including antimicrobial compounds [22–25]. Compared
with Aspergillus, Penicillium and Cladosporium, marine members of the genera Microscypha
and Sistotrema appear to be more limited in their diversity of secondary metabolites pro-
duced [26]. In general, filamentous fungi appear to have greater potential to produce
secondary metabolites than yeasts as evidenced here by the presence of a relatively high
occurrence of specific biosynthetic gene clusters. This is consistent with a previous study
based on deep subsurface fungi [8]. Surprisingly, none of the filamentous fungal isolates in
this study seemed to possess PKS/NRPS hybrid genes, not even Aspergillus and Penicillium
isolates, for which hybrid PKS/NRPS were detected in previous studies [8,27].
No specific distribution patterns of BGCs were visualized, neither correlating with
genus or species nor depending on the isolation depth (linear regression, p-values > 0.05),
thus illustrating high intraspecific variability.
2.2. Antimicrobial Activities
One of the aims of our biotechnological screening was to select the most promising
isolate candidates for bioactivity screening by examining our collection through the prism
of their genetic potential. Here, 23 fungal isolates (13 filamentous fungi and 10 yeasts)
were selected on this basis but also on the basis of their growth rate so that we avoided
slow-growing isolates. We recognized that this strategy may lead us to missing interest-
ing isolates but the idea here was to lower the number of tests for our one strain many
compounds (OSMAC)-like approach. In total, from the 1518 tests processed (23 isolates
grown on six media and tested against 11 microbial targets), 99 positive microbial activities
were observed which represented 6.5% of tested conditions. Among these 99 antimicrobial
activities, 83 were related to bactericidal/fungicidal activities (84%) and 16 to bacterio-
static/fungistatic ones (16%). Out of the 83 bactericidal/fungicidal activities, 71 were
against Gram-positive bacteria (70%), 25 against Gram-negative bacteria (25%) and 6
against the yeast Candida albicans (5%).
None of the yeasts tested (10 isolates) displayed an antimicrobial activity (data not
shown), which appears to be consistent with previous studies comparing yeasts to filamen-
tous fungi in terms of secondary metabolites [8,28]. This absence of antimicrobial activity
may reflect their lower observed genetic potential to produce secondary metabolites based
on the gene targets we selected, which was lower compared to the filamentous fungi we
examined. However, these observations may not extend to all yeasts or filamentous fungi.
As an example, the filamentous Leptosphaeria dryadis (UBOCC-A-118058) showed a high
genetic potential by having three of our targeted genes (type III PKS, NRPS and TPS), yet it
did not show any antimicrobial activities. This suggests that the gene targets we focused
on may play other roles in the growth of that fungus, and could possibly have antiviral,
immunosuppressive, anti-inflammatory, antioxidant or antitumor activities. They may
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also be involved in resistance to environmental biotic or abiotic stresses, as previously
shown [28–32]. In contrast, Penicillium olsonii (P. olsonii) (UBOCC-118169), which presented
a low genetic potential with two represented genes, showed high antimicrobial activities
against five pathogens, namely Escherichia coli (E. coli) ATCC 25922, Salmonella enterica
(S. enterica) CIP 8297, Pseudomonas aeruginosa (P. aeruginosa) ATCC 27853, Enterococcus fae-
calis (E. faecalis) CIP A 186 and Staphylococcus aureus (S. aureus) ATCC 25923 (Figure 2). This
taxon may potentially have additional genes for other secondary metabolites that were not
targeted in our study. Another possible explanation for some contrasting results is that our
designed primers likely do not target an exhaustive list of genes of interest. This molecular
screening can thus be viewed as providing potentially incomplete information on the po-
tential for secondary metabolite activity and appears as a filtering tool to lower the number
of isolates to be screened but which is not exempt from biases. A more complete, but ad-
mittedly more expensive and time-consuming, approach would be genome sequencing of
all isolates followed by gene analysis targeting synthesis of secondary metabolites through
the AntiSMASH tool [32–35]. This would produce a more complete picture of biosynthetic
gene clusters in each organism and would allow for chemical structure prediction and
networking approaches [36]. This would be the logical next step after conducting a large-
scale screening of a culture collection as done in this study. Finally, another explanation
to better understand these contrasting results is that our approach did not integrate the
dynamic nature of the fungal metabolome. Indeed, antimicrobial activity was screened at
one specific time frame (3 days for yeasts, and 7 to 14 days for filamentous fungi). However,
as demonstrated in a previous study based on time-scale metabolomics [37], only subsets
of BGCs are expressed at a given time, suggesting that only a fraction of the metabolome
was detected here.
The effect of the culture medium used for growth was also tested here. Based on the
99 positive hits for antimicrobial activities, 29, 24, 13, 12, 11 and 10 positive hits were ob-
tained from MEPA, PDA, Czapek, Wickerham-Chitin, Wickerham-Halogen and Wickerham
medium, respectively. This clearly highlights the importance of diversification of culture
media for this kind of screening and appears to be consistent with many metabolomic
studies that show the utility of the OSMAC approach for stimulating the marine fungal
metabolome [38–41]. Here, the MEPA medium, enriched with lignin, chitin and cellulose,
produced a relatively large number of positive hits. The presence of such complex polymers
seems to enhance the synthesis of antimicrobial compounds, which has, to the best of our
knowledge, not been previously reported.
Finally, 52% of the tested fungal isolates produced antimicrobial compounds. This is
consistent with a previous study that used a similar strategy, and highlighted that 33% of a
collection from deep subsurface sediments produces antimicrobial compounds [28], but
also with another one focusing on the antibacterial activity of marine fungi from the Arctic,
highlighting 50% of antibacterial activity against human pathogens [42]. Our results are
also in agreement with previous bioprospection screening reports that ~50% of microbial
isolates from the black coral Antipathes dichotoma exhibited antimicrobial activities [43] but
contrast with some reports showing ~10% activity for deep sediment bacteria [44] or for
microbial isolates obtained from sea anemone and holothurian samples [45]. In summary,
the deep biosphere and its associated fungal diversity is a promising reservoir of putatively
interesting biomolecules.
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2.3. Antimicrobial Activity against Multidrug-Resistant Bacteria
Based on the antimicrobial activity spectrum that we observed, it appears that two
isolates affiliated to P. olsonii (UBOCC-A-118169 and UBOCC-A-119011) and one isolate
affiliated to Aspergillus conicus (A. conicus) (UBOCC-A-118156) display the most interesting
antimicrobial profiles. Indeed, the isolates affiliated to P. olsonii were active against a
wide range of pathogens and the isolate affiliated to A. conicus was highly active against
S. aureus, regardless of the medium that was used to produce biomass (Figure 2). As the
Gram-negative bacterium P. aeruginosa and the Gram-positive bacterium S. aureus targets
were highly impacted by these isolates with obvious bactericidal activities, we decided
to conduct a second antimicrobial screening using multidrug-resistant P. aeruginosa and
S. aureus. The idea here was to generate biomass for these three isolates and to extract
secondary metabolites using different combinations of solvents in order to obtain crude
extracts to test for associated antimicrobial activities.
Preliminary results on crude extracts allowed us to confirm the antimicrobial activ-
ity of P. olsonii (UBOCC-A-118169) against S. aureus, and also revealed activity against
S. aureus MecA III. The obtained CMI were between 8–16 µg/mL and 4–8 µg/mL for
S. aureus and S. aureus MecA III, respectively. No activities were obtained from the crude
extracts obtained from the other strains, suggesting that the compound(s) responsible for
the detected antimicrobial activity was (were) not extracted using our methods.
2.4. Molecular Networking
Metabolomic fingerprints, associated with each organic extract (F1 and F2, see M&M),
were obtained by (i) HPLC-PDA-ELSD and (ii) UHPLC-HRESIMS (/MS), allowing us to
characterize the chemical diversity of the extracts, making the evaluation of the number,
the relative amounts, the chemical family and the molecular mass of the metabolites
constituting the extracts possible. HPLC-DAD-ELSD analyses of the organic extract F1
(EtOAc/CH2Cl2 extracts, see M&M) from the three strains revealed interesting chemical
fingerprints (Figure S1). The metabolomic profiles of the two P. olsonii (UBOCC-A-118169
and UBOCC-A-119011) isolates appeared similar. Regarding A. conicus (UBOCC-A-118156),
the organic extract exhibited one major metabolite and several eluted compounds late in
the series that are predicted to be fatty acids.
The MS/MS spectra for each metabolite were compared to several databases (Marin-
Lit, Dictionary of Natural Products (DNP), Natural Products Atlas (NPA), Scifinder and
Chemspider) and to published data [46–49]. The main compounds produced by the two
isolates affiliated to P. olsonii (UBOCC-A-118169 and UBOCC-A-119011) were assigned
to xanthoepocin and asperphenamate. Using a similar approach, the major compound
produced by A. conicus (UBOCC-A-118156) was assigned to asperphenamate.
To putatively annotate the fungal metabolites that may be responsible for the de-
tected antimicrobial activities, the organic extracts were analyzed by HPLC-HRMS to build
feature-based molecular networks. The graphical representation of the molecular network
(depicting the chemical space present in MS/MS experiments) of P. olsonii (UBOCC-A-
118169 (red), UBOCC-A-119011 (blue)) isolates using MS/MS data of each metabolite
constituting the crude organic extracts F1 allowed us to highlight 1447 nodes and 1805
edges which suggest the production of numerous metabolites (Figure 3). Almost all nodes
are common to both P. olsonii isolates, confirming the similarity of the metabolomic profiles.
Among the nodes, a comparison of the experimental MS/MS spectra with the ones avail-
able in GNPS Public Spectral Libraries (https://gnps.ucsd.edu/ProteoSAFe/libraries.jsp,
accessed date in March 2021) allows us to highlight a putative subcluster of xanthoepocin
containing 10 nodes and 12 edges, and a putative subcluster including asperphenamate con-
taining 40 nodes and 105 edges. The presence of different compounds in the same cluster
suggests the possibility of a common biosynthetic pathway or some metabolites that could
be analogues of xanthoepocin and asperphenamate, respectively. The UBOCC-A-119011
strain (blue) contains many putative xanthoepocin analogues, two of which are not present
in the UBOCC-A-118169 strain (red). Previous studies have shown that xanthoepocin in-
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hibits the growth of S. aureus and S. aureus MRSA with MICs of 1.56 µg/mL [47]. Although
asperphenamate is well known for its antitumor activity [50,51], it is inactive against the
microorganisms tested (S. aureus and MRSA) at up to 64 µg/mL [48]. Combining all these
results, but recognizing that our putative MS-based molecular networking annotation has
to be taken with caution, P. olsonii UBOCC-A-118169 and P. olsonii UBOCC-A-119011 may
produce xanthoepocin-like molecules as antibacterial secondary metabolites. Complemen-
tary analyses to isolate the xanthoepocin analogues produce by these strains would allow
access to new molecules with potential antibacterial activity.
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naming system proposed by Subko et al. (2021). Putative assigned analogues mainly differ
from asperphenamate by the type of amino acid, for example, asperphenamate Y is substi-
tuted by tyrosine instead of henylalanine. Asperphenidine is an analogue constituted by
phen lalanine and nicotinic acid (Figure 5). Rece tly, some ew natural asperphenamate
analogues have been isolated from several fungi, such as 4-OMe-asperphenamate [48,52]
and asperphenamates B and C [53]. Moreover, 22 new asperphenamate analogues were
isolated from Penicillium astrolabium and assigned by HRMS/MS. Some derivatives were ad-
ditionally confirmed by isolation, NMR analyses and structure elucidation [48]. Although
the antibacterial activity of these compounds has not been evaluated, asperphenamates Y
and W and asperphenidine F1 were evaluated against five cancer cell lines and moderate
activities were detected against breast, skin, liver and pancreas cell lines [49]. The large
number of nodes in the putative asperphenamate cluster within the A. conicus (UBOCC-A-
118156) molecular network may indicate that many analogues remain to be isolated and
characterized. Such analogues may be linked to antibacterial activity that we detected in
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P. conicus (UBOCC-A-118156) but, as emphasized for the P. olsonii MS-based molecular
network analyses, these results have to be taken with caution since the metabolites were
putatively assigned.
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3.1. Culture Collection
The analyzed culture collection comprises fungi isolated from deep lower oceanic
crust samples from below Atlantis Bank, the Indian Ocean, from 10 to 780 m below the
seafloor (mbsf) during the International Ocean Discovery Program Expedition 360 [10].
Several genetic markers were used to identify 128 fungal isolates, and isolates were ex-
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tensively characterized in terms of their ecophysiological and metabolic features to assess
their environmental relevance [11]. All isolates are preserved in the UBO Culture Col-
lection (https://www.univ-brest.fr/ubocc, accessed date in July 2021) and are available
upon request.
3.2. Occurrence of Genes Involved in Secondary Metabolite Anabolism
A selection of 75 fungal isolates from among the 128 isolates in the culture collection
was made based on taxonomy in order to cover the broadest extent of the culturable
diversity. Extracted DNA from each isolate was used as a template to amplify secondary
metabolite genes of interest, including types I and III polyketide synthase (PKS), non-
ribosomal peptide synthetase (NRPS), hybrid PKS/NRPS and terpene synthase (TPS)
genes, using degenerated primers and PCR conditions detailed in Rédou et al. (2015). A
value between 0 and 3 was assigned to represent the number of genes detected in each
isolate, as a proxy for their molecular potential; 0 meaning no detected genes, 1 meaning
1 gene, 2 meaning 2 genes and 3 meaning more than 2 genes.
3.3. First Screening—Agar Plug Diffusion Assay
Antimicrobial screening was conducted using six different media with a fixed concen-
tration of 3% sea salts. We used potato dextrose agar (PDA), Czapeck Dox medium (CZ),
Wickerham medium (W), MEPA supplemented with chitin and cellulose at 1 g/L (MP),
Wickerham supplemented with chitin at 5 g/L (WC), and Wickerham supplemented with
the halogens potassium bromide at 0.09 g/L, potassium chloride at 0.6 g/L and sodium
fluoride at 0.02 g/L (WH). Fungal isolates were inoculated on each medium at 20 ◦C and
grown for 3 days for yeasts, and 7 to 14 days for filamentous fungi, depending on their
growth rate. At the same time, 11 human microbial pathogens including Gram-negative,
Gram-positive and a yeast were precultured on tryptone salt broth (TSB) for 24 h at
30 ◦C or 37 ◦C depending on the pathogen. Specific agar media were inoculated with
each pathogen (Table 1) at a standardized concentration of 106 cells/mL. For the diffusion
assay, 12 agar plugs were removed from a selection of 23 fungal isolates at evenly spaced
locations on each yeast or bacterial pathogen plate and the empty holes were replaced
by agar plugs containing actively growing mycelium or yeast cells removed from the
6 different culture media. Each combination of pathogen and fungal isolate was tested in
triplicate and negative controls were included without fungal inoculation (agar plugs from
sterile media). Plates were then incubated at 30 ◦C or 37 ◦C for 72 h and observed every
24 h to differentiate bacteriostatic/fungistatic from bactericidal/fungicidal activities.
Table 1. Temperature conditions and media used for each of the 11 targeted human pathogens.
Microbial Pathogens Temperature Medium
Enterobacter aerogenes CIP 6086 30 ◦C TSB
Escherichia coli ATCC 25922 37 ◦C TSB
Klebsiella oxytoca CIP 7932 37 ◦C TSB
Pseudomonas aeruginosa ATCC 27853 37 ◦C TSB
Salmonella enterica CIP 8297 37 ◦C TSB
Yersinia enterocolitica ATCC 9610 30 ◦C TSB + NaCl
Enterococcus faecalis CIP A 186 37 ◦C TSB
Lactococcus garviae ATCC 43921 30 ◦C BHI
Listeria monocytogenes SOR 100 37 ◦C BHI
Staphylococcus aureus ATCC 25923 37 ◦C TSB
Candida albicans ATCC 90028 37 ◦C Yeast medium
3.4. Secondary Screening—Metabolite Extraction, Molecular Networking and Determination of the
Minimum Inhibitory Concentration
The most promising fungal isolates, based on the agar plug screening, were selected
for downstream analyses, including extraction of secondary metabolites and antimicrobial
assays on multidrug-resistant (MDR) pathogens. Around 80 Petri dishes were used to
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produce sufficient fungal biomass for each selected isolate. Dried biomass was suspended
in 50 mL of a mixture of EtOAc:CH2Cl2 (1:1, v/v), homogenized with an Ultra Turrax (IKA,
USA) device, extracted three times by sonication with 50 mL of EtOAc:CH2Cl2 (1:1, v/v)
and filtered. The combined filtrates were evaporated under reduced pressure to yield a
first crude organic extract (F1). The biomass was then suspended in 50 mL of a mixture of
MeOH:CH2Cl2 (1:1, v/v), extracted three times by sonication with 50 mL of MeOH:CH2Cl2
(1:1, v/v) and filtered. The combined filtrates were evaporated under reduced pressure
to yield a second crude organic extract (F2). Each crude organic extract, F1 and F2, was
first re-suspended in a mixture of MeOH:CH2Cl2 (1:1, v/v) to reach a final concentration of
10 mg/mL and then analyzed by HPLC-PDA-ELSD. The latter was performed with a
Waters Alliance 2695 high-performance liquid chromatography (HPLC) system (Waters
Corporation, Milford, MA, USA) coupled with a Waters 996 photodiode array detector and
a Sedex 55 evaporative light-scattering detector (SEDERE, France), using a bifunctional
Macherey-Nagel NUCLEODUR® Sphinx RP column (250 × 4.6 mm, 5 µm) consisting
of a balanced ratio of propylphenyl and C18 ligands. The mobile phase was composed
of H2O (plus 0.1% HCO2H) and acetonitrile (CH3CN plus 0.1% HCO2H) and the fol-
lowing gradient was used: H2O:CH3CN 90:10 for 5 min, H2O:CH3CN 90:10 to 0:100 for
30 min, 0:100 for 5 min, 0:100 to 90:10 for 15 min (flow: 1.0 mL·min−1, injection volume:
20 µL). Chromatograms were extracted at the following detection wavelengths for visual
inspection: 214, 254 and 280 nm. Moreover, each crude organic extract was analyzed by
HPLC/ESI-MS/MS in both positive and negative ion modes using a Vanquish UHPLC
coupled with a Thermo Q-Exactive (UPLC-HRMS) Orbitrap (Thermo Fisher Scientific
GmbH, Bremen, Germany) and an ESI source operated with the Xcalibur (Version 2.2, Ther-
moFisher Scientific) software package. A bifunctional Macherey-Nagel NUCLEODUR®
Sphinx RP column (150 × 4.6 mm, 3 µm) consisting of a balanced ratio of propylphenyl
and C18 ligands was used with an injection volume of 5 µL and a flow rate of 0.3 mLmin−1.
The mobile phase was composed of H2O (plus 0.1% HCO2H) and acetonitrile (CH3CN
plus 0.1% HCO2H) and the following gradient was used: H2O:CH3CN 90:10 for 5 min,
H2O:CH3CN 90:10 to 0:100 for 30 min, 0:100 for 5 min, 0:100 to 90:10 for 15 min. HR-
MS/MS raw data files were converted from RAW to mzXML format using MSConvert
software, and clustered with MS-Cluster using Global Natural Products Social Molecular
Networking (GNPS) [21]. Molecular networks were created using the online workflow of
GNPS. The following settings were used for generation of the P. olsonii molecular network:
minimum pairs cos 0.7; parent mass tolerance, 0.02 Da; ion tolerance, 0.02; network topK,
6; minimum matched peaks, 7; minimum cluster size, 2. The following settings were
used for generation of the A. conicus molecular network: minimum pairs cos 0.8; parent
mass tolerance, 0.02 Da; ion tolerance, 0.02; network topK, 6; minimum matched peaks, 7;
minimum cluster size, 2. Data were visualized and analyzed using Cytoscape 3.8.1 [54].
The obtained dried crude organic extracts were dissolved in pure dimethyl sulfoxide
(DMSO) and integrated into TSB medium used here to culture the 8 selected pathogens.
The concentration range tested for each crude extract was between 256 µg/mL and
2 µg/mL (7 two-fold dilutions) in a 96-well plate. Suspensions of pathogens were calibrated
at 106 cells/mL. The final concentration of DMSO was less than 1% in each condition and
did not affect the microbial growth (as visualized in our positive controls). Among the
8 selected pathogens, 4 bacteria were multidrug resistant (Table 2). Plates were incubated
at 37 ◦C for 48 h. To highlight the minimum inhibitory concentration (MIC), bacterial
growth was determined using laser nephelometry (BMG Labtech), used here as a mid-
throughput method to assess bacterial growth. Finally, the MIC was described as the lowest
concentration that resulted in complete inhibition of microbial growth, as described in
CLSI standard M07-A9.
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Table 2. Tested human pathogens for the second antimicrobial screening.
Basic Pathogens MDR Pathogens
Enterococcus faecalis CIP A 186 Pseudomonas aeruginosa VIM2
Staphylococcus aureus ATCC 25923 Pseudomonas aeruginosa Brse
Escherichia coli ATCC 25922 Staphylococcus aureus MecC
Pseudomonas aeruginosa ATCC 27853 Staphylococcus aureus MecA III
4. Conclusions
Out of 75 fungal isolates (filamentous fungi and yeasts) selected from a collection
of 128 deep oceanic crust fungi, 62 were identified as putatively interesting based on the
presence of genes usually involved in the production of secondary metabolites. Based on
the pattern of BGCs that each isolate contained, 23 isolates were screened for antimicrobial
activities using an OSMAC-like approach. This screening highlighted 12 isolates showing at
least one antibacterial and/or antifungal activity (static or lytic) against human pathogens.
Approximately ~55% of the 23 targeted isolates showed activity. Among the 11 pathogens
tested, the Gram-positive bacterial strains S. aureus ATCC 25923 and E. faecalis CIP A
186 were the most impacted by the fungal strains tested, followed by the Gram-negative
bacterium P. aeruginosa ATCC 27853. Three fungal isolates were selected based on their
demonstrated antimicrobial potential when tested against a multidrug-resistant S. aureus.
Out of these three isolates, crude extracts from P. olsonii (UBOCC-A-118169) revealed antimi-
crobial activity against this pathogen. Finally, a metabolomic approach based on molecular
networking allowed us to examine the metabolome of these three isolates and highlighted
the putative occurrence of numerous compounds for which complementary analyses are
needed. Indeed, our strategy here was to highlight the biotechnological potential of a
unique and invaluable collection of deep oceanic crust fungal isolates using a polyphasic
approach merging genetic mining and antimicrobial screening. The constellations of pu-
tative compounds and their analogues visualized using MS-based molecular networking
definitely call for in-depth analyses in order to obtain larger amounts of biomass and thus
finely characterize each compound. This study demonstrates that fungi from uncharted
extreme habitats display untapped biotechnological potential and that the deep sea, and
more precisely, the deep biosphere, may harbor a complex diversity of novel compounds
waiting to be characterized.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/md19080411/s1, Figure S1: Comparative analyses of the HPLC-PDA-ELSD chemical fin-
gerprints of the crude organic extracts F1 of (a) (UBOCC-A-118169 P. olsonii), (b) (UBOCC-A-119011
P. olsonii) and (c) (UBOCC-A-118156 A. conicus) dichloromethane-ethyl acetate extracts obtained with
HPLC-DAD-ELSD (Macherey-Nagel propylphenyl-C18, 250 × 4.6 mm; 5 µm, gradient: CH3CN +
0.1% formic acid (FA), H2O + 0.1% FA, 10:90 to 100:0 in 30 nm).
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